Published in Physician Law Weekly, October 12th, 2005
Eisai is seeking approval for two indications for rufinamide, as adjunctive therapy for Lennox-Gastaut syndrome (LGS) in children ages 4 and over and as adjunctive therapy for partial-onset seizures with and without secondary generalization in adults and adolescents (12 years of age and over).
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.